Trinity Biotech

Trinity Biotech plc is a commercial-stage biotechnology company headquartered in Dublin, Ireland, focused on human diagnostics and diabetes management solutions including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems for the point-of-care and clinical laboratory segments and has expanded into the wearable biosensor and data-center liquid-cooling infrastructure segments through recent acquisitions. Trinity Biotech is dual-listed on Nasdaq and announced a 1-for-30 reverse ADS split in July 2026 intended to regain Nasdaq minimum-bid-price compliance.